Sales of Edwards Lifesciences’ Sapien transcatheter aortic valve replacement (TAVR) systems have bounced back to pre-pandemic levels as hospitals have found ways to continue these life-saving procedures despite the risks of COVID-19.
In the third quarter of 2020, global sales of Edwards’ TAVR systems were $745m, 6% higher than in the third quarter of 2019 and about 25% higher than the second quarter of 2020